Climb Bio, Inc. (CLYM)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on CLYM

With Tiblio's Option Bot, you can configure your own wheel strategy including CLYM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CLYM
  • Rev/Share 0.0
  • Book/Share 3.2729
  • PB 0.4003
  • Debt/Equity 0.0025
  • CurrentRatio 31.4078
  • ROIC -0.3861

 

  • MktCap 88524298.0
  • FreeCF/Share -0.2404
  • PFCF -5.6885
  • PE -1.1476
  • Debt/Assets 0.0024
  • DivYield 0
  • ROE -0.3893

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CLYM Oppenheimer -- Outperform -- $10 June 6, 2025
Initiation CLYM BTIG Research -- Buy -- $7 May 22, 2025

News

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
CLYM
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.

Read More
image for news Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Climb Bio to Present at Upcoming Investor Conferences
CLYM
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below.

Read More
image for news Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
CLYM
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.

Read More
image for news Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

About Climb Bio, Inc. (CLYM)

  • IPO Date
  • Website https://eliemtx.com
  • Industry Biotechnology
  • CEO Aoife M. Brennan BAO, BCh, MB, MMSc
  • Employees 17
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.